Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M101488200 on September 10, 2001

J. Biol. Chem., Vol. 276, Issue 45, 41803-41809, November 9, 2001
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
276/45/41803    most recent
M101488200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Takeda, M.
Right arrow Articles by Watanabe, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Takeda, M.
Right arrow Articles by Watanabe, S.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Cell Cycle-dependent Interaction of Mad2 with Conserved Box1/2 Region of Human Granulocyte-Macrophage Colony-stimulating Factor Receptor Common beta c*

Mitsuo TakedaDagger §, Naoshi Dohmae, Koji Takio, Ken-ichi AraiDagger §, and Sumiko WatanabeDagger ||

From the Dagger  Department of Molecular and Developmental Biology, Institute of Medical Science, § Core Research for Evolutional Science and Technology, Japan Science and Technology Corporation, University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan, and the  Biomolecular Characterization Division, RIKEN (Institute of Physical and Chemical Research), 2-1, Hirosawa, Wako-shi, Saitama 351-0198, Japan

Received for publication, February 16, 2001, and in revised form, September 7, 2001


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Box1 and 2 (box1/2) are conserved cytoplasmic motifs located in the membrane proximal region of cytokine receptors, including the human granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor common beta c. Deletion of box1/2 abrogated all the examined activities of GM-CSF, and this phenomenon is explained by the loss of binding by Jak2. To test if a molecule other than Jak2 interacting with the box1/2 region plays a role in GM-CSF receptor signal transduction, we screened for molecules interacting with the box1/2 region by a pull-down assay using recombinant purified protein of GST fused with the beta c box1/2 region and a Ba/F3 cell lysate. The mouse homologue of Mad2 protein, which plays an important role in the M phase of the cell cycle, was revealed to associate with the box1/2 region specifically. Peptides corresponding to the box1 sequence also bound to Mad2, and mutation of the box1 decreased the Mad2 interaction. Deletion analysis indicated that interaction with box1/2 occurred through the C-terminal portion of Mad2. Mad2 is known to change affinity for binding partners cell cycle dependently. Binding affinity of Mad2 to box1/2 increased in the late M phase, suggesting the possibility that GM-CSF participates in regulation of the M phase check point through interaction with Mad2.


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Granulocyte-macrophage colony-stimulating factor (GM-CSF)1 is a cytokine that stimulates the proliferation and differentiation as well as survival of various hematopoietic cells (1). The receptor of human (h) GM-CSF (GM-CSFR) consists of two subunits, alpha  and beta , both of which are members of the cytokine receptor superfamily (2). The alpha  subunit is specific to hGM-CSFR, whereas the beta  subunit (beta c) is shared by IL-3, GM-CSF, and IL-5 receptors (2). GM-CSF induces tyrosine phosphorylation of beta c and various cellular proteins and activates early response genes such as c-fos, c-jun, and c-myc, as well as stimulates cell proliferation in hematopoietic cells and fibroblasts (3). GM-CSF activates various signaling molecules, including Jak2, STAT5, mitogen-activated protein kinase cascade kinases, and phosphatidylinositol 3-kinase (2). beta c contains box1 and box2 regions (box1/2), which are conserved among the cytokine receptor superfamily, and 8 tyrosine residues located in its cytoplasmic region (4, 5). To better comprehend signaling events involved in cell proliferation, we and others analyzed biological activities of various mutants of beta c (6-8) and found that the box1 region was essential for all of the hGM-CSFR signals we examined. Although the box1/2 region is essential and sufficient for cell proliferation and survival, a tyrosine residue(s) is also required for mitogen-activated protein kinase and c-fos promoter activation (8, 9). Because box1 is assumed to bind Jak2, it is likely that activation of Jak2 is sufficient and essential for hGM-CSF signals through interaction with the box1 region of beta c. This notion was supported by observations that dominant negative Jak2 suppressed all the GM-CSFR signaling and activities we investigated (7). In addition, Jak2 knockout mice showed defects in GM-CSF-dependent colony formation (10, 11).

The box1 region contains the proline-X-proline sequence, which is conserved among members of the cytokine receptor superfamily (12). Mutation analysis of the motif suggested a crucial role for the motif in a variety of receptor-mediated signalings. The G-CSF receptor mutant in which the conserved proline-X-proline is substituted by Ala-X-Ala can induce neither DNA synthesis nor cell proliferation (13). The mutant growth hormone receptor failed to induce either cell proliferation or spi-1 induction (14, 15). Similar results were obtained in the case of gp130 and the prolactin receptor (12, 16, 17). Although the importance of the box1 region in various receptors has been noted, structural information about this region has been awaited. Thus, the role and mechanism of box1 function have remained unsolved.

We have now identified Mad2 (mitotic arrest-deficient 2) protein as a box1/2-binding protein. Mad2 was first discovered as a gene responsible for the mitotic checkpoint in yeast (18). The knockout of Mad2 in mice showed that Mad2 is essential in mouse cells after embryonic day 6.5, although it is dispensable for normal cell division in yeast (19). During mitosis, Mad2 localized at an unattached kinetochore monitors for correct spindle-kinetochore attachment, a prerequisite for initiation of anaphase (20). The Mad2-dependent monitoring system, maintained until the completion of spindle attachment, prevents anaphase initiation through Mad2-Cdc20 complex formation (21-23). Cdc20 activates the ubiquitin ligase activity of anaphase promoting complex (APC), after which the activated APC promotes the initiation of anaphase. There are a variety of Mad2 binding partners, including molecules not related to the mitotic checkpoint (24-27). Here, we found that hGM-CSFR beta c acts as one of such partners of Mad2 and that their interaction is regulated in a cell cycle-dependent manner.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Reagents-- Recombinant murine IL-3 (mIL-3) expressed in silkworms, Bombyx mori, was purified as described (28). Recombinant hGM-CSF was a gift from Schering-Plough (Madison, NJ). Antibodies anti-hGM-CSF receptor beta c (S-16, C-20) and anti-GST (B-14) were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-Mad2 was from Transduction Laboratory (Lexington, KY), and anti-phosphotyrosine (4G10) from Upstate Biotechnology Inc (Lake Placid, NY). Peptides were synthesized by using Fmoc (N-(9-fluorenyl)methoxycarbonyl) chemistry with a Shimadzu PSSM-8 synthesizer (Shimadzu, Kyoto, Japan). All the peptides were designed to have a cysteine at their N terminus for iodoacetamido-based sulfhydryl conjugation. Each peptide was conjugated with SulfoLink coupling gel (Pierce) according to the manufacturer's instruction. Peptide corresponding to CAGGPPGGPQVNPIPVTDEVV served as a control.

Plasmid Construction-- The plasmids encoding GST fusion protein were constructed by using pGEX vectors (Amersham Pharmacia Biotech, Uppsala, Sweden). GST-box1/2 was constructed by PCR amplification of the box1/2 region corresponding to amino acids 453-544, and termination was generated after residue 544 (aspartic acid) by PCR mutagenesis. Sequences of primers used for introduction of mutation were 5'-ATGTGATCAGGCTGCGCAGAAAGTG-3' and 5'-CGGAATTCTAATCTGAGGCAGCTGGAG-3'. Amplified fragments were inserted into BclI and EcoRI sites of pGEX-3X. For GST-alpha , hGM-CSFR alpha  subunit was digested with CvnI and XhoI. The resulting fragment, which contained almost the entire region of the cytoplasmic region of the alpha  subunit, was inserted into pBS-SK (Stratagene, La Jolla, CA) at SmaI (blunted) and XhoI sites. Then, the fragment was isolated by BamHI and XhoI digestion and inserted into BamHI and XhoI sites of the pGEX-5X-1 vector.

His-tagged recombinant proteins were constructed by using the QIAexpressionist type IV pQE vector (Qiagen, Chatsworth, CA) to contain 6 histidines at their N terminus. An XhoI site was created immediately before the initiation codon of Mad2 by PCR mutagenesis, and the entire region of Mad2 was isolated by cleavage at XhoI and HindIII sites. The fragment was inserted into pQE-31 at SalI and HindIII sites. The N terminus deletion mutant was made by insertion of Sau3AI and SacI fragment into pQE-31 BamHI and SacI sites. C terminus deletion was made by deletion of the region after the DpnI site. The DpnI site was blunted and ligated to the blunted SmaI site of the pQE-31 vector. For mammalian expression, the fragment encoding full-length wild-type Mad2 (prepared by XhoI and SpeI sites from pCR2.1 vector; Invitrogen, Carlsbad, CA) was inserted into XhoI and SpeI sites of the pKU2 vector, which contains the SRalpha promoter (29).

Recombinant Protein Expression and Purification-- Plasmids encoding GST fusion proteins were introduced into BL21 cells (Escherichia coli strain), and GST fusion protein expression was induced by adding 1 mM IPTG. The cells were lysed by sonication, and the overexpressed protein was purified on an affinity column packed with glutathione-Sepharose4B (Amersham Pharmacia Biotech), according to the manufacturer's instruction.

The histidine-tagged proteins were expressed in M15 cells (E. coli strain carrying a pREP4 plasmid), and purification of the protein was done by using an Ni2+-nitrilotriacetic acid-agarose (Qiagen, Chatsworth, CA) affinity column, according to the manufacturer's instruction. The eluents were dialyzed against 20 mM Tris-HCl, pH 7.5, and protein concentrations were determined by using a BCA protein assay kit (Pierce).

Cell Culture and Cell Lysate Preparation-- The mouse IL-3-dependent, pro-B cell line Ba/F3 stably expressing both alpha  and beta  subunits of hGM-CSFR (Ba/F-wild) was maintained in RPMI 1640 containing 5% fetal calf serum, 0.25 ng/ml mIL-3, 50 units/ml penicillin, and 50 µg/ml streptomycin. HeLa cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum, 50 units/ml penicillin, and 50 µg/ml streptomycin. Whole cell lysates used for pull-down assay and immunoprecipitation were prepared by using lysis buffer (40 mM Tris-HCl, pH 7.6, 50 mM KCl, 0.25% Nonidet P-40, 2 mM EDTA, 50 mM NaF, 20 mM beta -glycerophosphate, 1 mM NaVO4, 10 mM 2-mercaptoethanol, 1 mM phenylmethylsulfonyl fluoride, 2 µg/ml aprotinin, 1 µg/ml pepstatin A, 10 µg/ml leupeptin). The undissolved fraction of the lysate was removed by centrifugation (15,000 × g for 30 min). Fractionation of HeLa cell lysates into cytoplasm and nucleus portions was done as follows. Briefly, the cells were incubated in hypotonic buffer (10 mM Hepes, pH 7.9, 10 mM KCl, 2 mM MgCl2, 0.1 mM EDTA, 1 mM dithiothreitol, 0.1 mM phenylmethylsulfonyl fluoride) for 15 min. Nonidet P-40 was added to the cell suspension at a final concentration of 0.6%. The Nonidet P-40-insoluble fraction (enriched in nuclei) was separated by centrifugation (15,000 × g for 30 s). The pellets were washed with hypotonic buffer two times and incubated in extraction buffer (50 mM Hepes, pH 7.9, 50 mM KCl, 300 mM NaCl, 0.1 mM EDTA, 1 mM dithiothreitol, 0.1 mM phenylmethylsulfonyl fluoride, 10% glycerol) for 20 min. Both Nonidet P-40-soluble and -insoluble fractions were diluted with an excess amount of the lysis buffer used in the pull-down assay.

Pull-down Assay and Immunoprecipitation-- The lysate (108 cells/ml) prepared from Ba/F wild cells was incubated overnight at 4 °C with GST fusion proteins and glutathione Sepharose. GST fusion protein and associated protein(s) were eluted with 15 mM glutathione and dialyzed against 20 mM Tris-HCl, pH 7.5. The samples were lyophilized and dissolved in suitable buffer for further analyses.

For immunoprecipitation analysis, cell lysates (2 × 107 cells/samples) were incubated with an appropriate antibody and protein G-Sepharose 4 FF (Amersham Pharmacia Biotech) overnight at 4 °C. The bands were visualized by using an ECL Western blotting detection system (Amersham Pharmacia Biotech).

For preparation of cell cycle-synchronized cell lysates, HeLa cells were arrested at the G1/S boundary by a double-thymidine block (30). Briefly, HeLa cells were treated for 14 h with Dulbecco's modified Eagle's medium containing 2 mM thymidine, released for 10 h in normal medium, and then treated again with thymidine for 14 h. There after, the cells were released in normal medium and harvested after incubation for the times indicated in the figures. For Ba/F3 cells, cells were depleted of mIL-3 for 12 h to become arrested in the G1 phase. hGM-CSF (2 ng/ml) was then added, and the cells were harvested at the indicated time points. The phase of the cell cycle was confirmed by examining DNA contents by propidium iodide staining and flow cytometry (FACScan, Becton Dickinson, San Jose, CA). The lysates from each time point were prepared as described above. Protein amounts of the lysates were quantified with a BCA protein assay kit (Pierce) to confirm equal extraction efficiency among the samples. The lysate from each time point was divided into two tubes, and incubated with anti-beta c antibody (2 µg, for Ba/F3 cells), GST-box1/2 purified protein (for HeLa cells), or anti-p55CDC antibody (2 µg). Associated proteins were precipitated either with glutathione-Sepharose beads or protein G beads and separated by SDS-PAGE followed by Western blotting using anti-Mad2 antibody.

Electrophoresis, Blotting, Amino Acid Sequence, and Cloning of cDNA-- Two-dimensional electrophoresis, a combination of isoelectric focusing and SDS-PAGE, was carried out according to O'Farrell (31). Protein spots were detected either by silver staining or Western blotting. Silver staining of the PAGE gel was done with a 2D Silver Stain II kit (Daiichi Pure Chemicals Co. Ltd., Tokyo, Japan). For Western blotting, proteins were transferred to a polyvinylidene difluoride membrane (Millipore, Bedford, MA) by using a semidry type apparatus (model BE-320; Bio-Craft Co. Ltd., Tokyo, Japan) and the blotted membrane was incubated with appropriate antibodies.

For amino acid sequencing, two-dimensional separated gels were stained with 0.25% Coomassie Brilliant Blue and bands of 25 and 75 kDa were excised and treated with 0.2 µg of Achromobacter protease I (a gift from Dr. Masaki, Ibaraki University (Ref. 32)) at 37 °C for 12 h in 0.1 M Tris-HCl, pH 9.0, containing 0.1% SDS. The peptides generated were extracted from the gel and separated on columns of DEAE-5PW (2 × 20 mm; Tosoh, Tokyo, Japan) and Mightysil RP-18 (2 × 50 mm; Kanto Chemical, Tokyo, Japan) connected in series with a model 1100 (Hewlett Packard, Palo Alto, CA) liquid chromatography system. Peptides were eluted at a flow rate of 0.1 ml/min, with a linear gradient of 0-60% solvent B, where solvents A and B were 0.09% (v/v) aqueous trifluoroacetic acid and 0.075% (v/v) trifluoroacetic acid in 80% (v/v) acetonitrile, respectively. Selected peptides were subjected to Edman degradation in a model 477A automated protein sequencer (PerkinElmer Life Sciences) connected on-line to a model 120A PTH analyzer (PerkinElmer Life Sciences) and also examined by matrix-assisted laser desorption ionization time of flight mass spectrometry with a Reflex MALDI-TOF (Bruker-Franzen Analytik, Bremen, Germany) in linear mode, with 2-mercaptobenzothiazole used as a matrix. For cloning of full-length mouse Mad2 cDNA, PCR primers were designed according to the GenBankTM mouse Mad2 equivalent sequence of expressed sequence tag. PCR fragments were recovered by used of a TA vector (pCR2.1, Invitrogen, Carlsbad, CA), and the sequence was confirmed by using an ABI PRISM 310 sequencer (PerkinElmer Life Sciences).

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Isolation of Box1/2-interacting Proteins by Pull-down Analysis-- To determine whether proteins other than Jak2 bind to the box1/2 region, we conducted pull-down assays using the recombinant box1/2 region of beta c and Ba/F3 cell lysates. GST protein fused with the beta c box1/2 region (GST-box1/2) or the cytoplasmic region of alpha  subunit (GST-alpha ) were constructed, as shown in Fig. 1A. GST-box1/2, GST-alpha , and GST protein were purified by using a glutathione column and then incubated with the Ba/F3 cell lysate. Proteins were precipitated by glutathione-Sepharose 4B beads and analyzed by two-dimensional electrophoresis. To identify GST protein-binding proteins derived from E. coli, purified GST-box1/2, GST-alpha fusion proteins, and GST protein were also subjected to two-dimensional electrophoresis, and all the gels were silver-stained. We then compared the six panels precisely and found two proteins that specifically bound to GST-box1/2. Fig. 1B shows the pattern of GST-box1/2-binding proteins, and arrows indicate specific binding proteins with approximate molecular masses of 25 and 75 kDa. The 25-kDa protein was not detected in samples prepared with GST or GST-alpha , and only a residual amount of the 75-kDa one co-precipitated with GST or GST-alpha . Because these proteins were not observed in the gel with GST-box1/2 protein alone, these were probably specific binding proteins that had originated from Ba/F3 cells. We excised these spots and subjected them to microsequencing. The amino acid sequence revealed that two fragments derived from the 75-kDa protein were contained in GRP78 protein (33). Because GRP78 exclusively localizes in the endoplasmic reticulum and its structure is closely related to Hsp-70 (33), we speculate that the binding of GRP78 to GM-CSFR is an artificial event only observed in an in vitro system. A fragment derived from the 25-kDa protein corresponded to amino acids 193-199 of the human Mad2 protein. As the 25-kDa spot was recognized by an anti-Mad2 antibody in two-dimensional Western blotting analysis (data not shown), this 25-kDa protein is probably the mouse counterpart of the human Mad2. We also analyzed the immunoreactivity of the anti-Mad2 antibody toward GST protein-precipitated proteins by SDS-PAGE followed by Western blotting. The anti-Mad2 antibody recognized a band with a molecular mass of 25 kDa, and this band was observed only with the GST-box1/2 samples incubated with the Ba/F3 cell lysate (Fig. 1C, lane 7).


View larger version (20K):
[in this window]
[in a new window]
 
Fig. 1.   Pull-down assay of Ba/F3 cell lysates and GST proteins fused with hGM-CSF receptor. A, schematic representation of GST-alpha and GST-box1/2, which contain GST portion fused with cytoplasmic region of hGM-CSFR alpha  subunit and box1/2 region of beta c, respectively. AH is the conserved alpha  homology region. TM, transmembrane. B, silver staining pattern after two-dimensional gel electrophoresis of GST-box1/2-binding proteins. Pull-down assay was done by using GST-box1/2, GST-alpha , or GST itself, and co-precipitated proteins were separated by two-dimensional electrophoresis. Purified GST proteins themselves were also applied to two-dimensional electrophoresis. A total of six panels were carefully compared, and two proteins that bound to the GST-box1/2 specifically were identified. Panel shows the pattern of proteins binding to GST-box1/2, and specific proteins are indicated by the arrows. IEF, isoelectric focusing. C, Western blotting pattern of GST protein-binding proteins. GST-box1/2, GST-alpha , or GST itself was incubated with or without Ba/F3 cells lysate, and proteins precipitated with GSH beads were separated by SDS-PAGE. Proteins were transferred to a polyvinylidene difluoride membrane, and Western blotting was done with anti-Mad2 antibody. D, co-immunoprecipitation of Mad2 and hGM-CSFR beta c. Immunoprecipitation (IP) was done by using Ba/F3 cell lysate with anti-beta c or control IgG and was followed by Western blotting. The blotted protein was detected with anti-Mad2 antibody. The arrow indicates Mad2 detected with anti-Mad2 antibody.

To determine whether the endogenous full-length beta c protein binds to Mad2, we carried out co-immunoprecipitation analysis, using anti-beta c antibody (specific for human beta c) and Ba/F3 cells expressing hGM-CSFR. As shown in Fig. 1D, Mad2 protein co-immunoprecipitated with beta c, thereby suggesting an association of Mads with the native receptor.

We next asked whether this association is direct, and for this we used a binding assay of recombinant Mad2 and box1/2 proteins. Full-length mouse Mad2 coding region cDNA was isolated by PCR using synthesizing primers according to GenBankTM mouse Mad2 equivalent sequences. The recently published sequence of the mouse Mad2 (19) completely matched the sequence of our PCR product. To obtain purified Mad2 for the binding assay, we constructed histidine-tagged Mad2 protein (His-Mad2) and purified it. Then, binding activity of His-Mad2 protein and GST-box1/2, GST-alpha , or GST proteins was examined. As shown in Fig. 2 (lanes 1-3), when the protein complex was precipitated with glutathione-Sepharose 4B beads, only the GST-box1/2 co-precipitated with His-Mad2. Likewise, when proteins were precipitated by Ni2+ beads, again only the GST-box1/2 co-precipitated with the His-Mad2 protein (lanes 10-12). In contrast, neither GST-alpha nor GST was precipitated together with His-Mad2. Lanes 4-6 and 7-9 indicate that nearly the same amount of proteins precipitated in each lane. These results indicate that Mad2 association with box1/2 is specific and direct.


View larger version (46K):
[in this window]
[in a new window]
 
Fig. 2.   Binding analysis of interaction between recombinant purified His-Mad2 and GST-box1/2 proteins. Purified recombinant histidine-tagged Mad2 (His-Mad2) was incubated either with GST-box1/2, GST-alpha , or GST itself, and proteins were precipitated with glutathione-Sepharose 4B beads (lanes 1-3 and 7-9) or Ni2+-nitrilotriacetic acid-agarose beads (lanes 4-6 and 10-12). The precipitated proteins were separated through an acrylamide gel, and Western blotting was done with anti-Mad2 antibody (lanes 1-6) or anti-GST antibody (lanes 7-12).

Amino Acid Sequence of Box1/2 Required for Mad2 Binding-- We next examined the requirement of the box1/2 sub-region for binding to Mad2 protein, using a beta c-derived peptide conjugated with SulfoLink beads. Various peptides corresponding to a portion of the box1/2 region or its derivatives were synthesized and conjugated with SulfoLink beads at their N-terminal cysteine residue (Fig. 3A). The association with Mad2 was examined by incubating these peptides with Ba/F3 cell lysate, and the proteins that bound to the peptide beads were precipitated and separated by SDS-PAGE. Fig. 3B shows the Western blotting pattern obtained by using anti-Mad2 antibody for reaction with the precipitated proteins. Mad2 co-precipitated with the peptide-beads that covered the entire box1 region (lane 2). We next examined the binding potential of various box1/2-derived peptides. Neither box2 peptide nor control peptide precipitated Mad2 protein (lanes 4 and 7). Amino acids "PNP" conserved within box1 region of many cytokine receptors are thought to be critical for signal transduction as determined by mutation analysis of several receptors (12). When a peptide carrying a mutation within this conserved PNP motif (box1/ANA) was used for precipitation, the amount of co-precipitated Mad2 was significantly reduced (lane 3). It was also reported that 8 amino acid residues are critical for receptor activation (7, 34). The box1 peptide, which lacks these critical residues (Delta Box1), abrogated Mad2 precipitation (lane 6). The peptide corresponds to a joint region of box1 and box2 also could not precipitate Mad2 (lane 5). These results suggest that the conserved region of box1 plays an important role in binding to Mad2 protein. We also checked direct binding between recombinant purified His-Mad2 and these peptides, and essentially the same results (data not shown) as obtained with the Ba/F3 cell lysate emerged.


View larger version (11K):
[in this window]
[in a new window]
 
Fig. 3.   Analysis of the requirement of a region of box1/2 for binding with Mad2 by use of peptides corresponding to the box1/2 sequence. A, peptides corresponding to the box1/2 region are schematically shown. B, the peptides conjugated with SulfoLink coupling gel were mixed with Ba/F3 cell lysates and precipitated. Precipitates were separated through acrylamide gel, and Western blotting was done with anti-Mad2 antibody.

Region of Mad2 Required for Binding to beta c-- To analyze the region of Mad2 required for binding to beta c, we next constructed deletion mutants of Mad2, as schematically shown in Fig. 4A. Mutants were fused at their N terminus with a histidine tag for purification. Purified histidine-tagged Mad2 mutant proteins were incubated with purified GST box1/2, and the proteins were precipitated using glutathione-Sepharose 4B beads and analyzed by Coomassie Brilliant Blue staining (Fig. 4B). The GST-box1/2 could bind wild type (lane 2) as well as mutant Mad2 lacking the N-terminal portion (Delta N, lane 4), but the amount of precipitated Delta N-Mad2 was clearly less than that of the wild-type Mad2, thus indicating that the N-terminal region of Mad2 was not essential for but influenced the binding affinity between Mad2 and box1/2. In contrast, mutant Mad2 lacking the C terminus (Delta C) did not bind to GST-box1/2 (lane 3). In view of these data, we speculate that the C-terminal portion (54 residues, amino acid positions 152-205) is sufficient and is required to interact with GST-box1/2. The anti-Mad2 antibody, which recognizes the Delta N mutant but not the Delta C mutant interfered with the association between box1/2 protein and Mad2 of Ba/F3 lysates, in a dose-dependent manner (Fig. 4C). In contrast, control antibodies, anti-gamma -catenin, and anti-phosphotyrosine (4G10), did not affect Mad2 binding, thereby supporting the conclusion that the C-terminal region of Mad2 is important and sufficient for binding between box1/2 and Mad2.


View larger version (41K):
[in this window]
[in a new window]
 
Fig. 4.   Region of Mad2 required for binding to box1/2. A, mutants of Mad2 lacking either the C-terminal or N-terminal portion were constructed. The mutants and wild type contained a histidine tag at their N terminus. B, binding of mutants of Mad2 to purified GST-box1/2. Purified recombinant mutant His-Mad2 proteins were incubated with purified GST-box1/2, and the proteins were co-precipitated by using glutathione-Sepharose 4B beads and analyzed by SDS-PAGE followed by Coomassie Brilliant Blue staining. C, effect of addition of anti-Mad2 antibody to the association between GST-box1/2 and Mad2. Ba/F3 lysate was incubated with GST-box1/2 in the presence of various amounts of anti-Mad2 antibody or control antibody. Proteins were co-precipitated and analyzed by Western blotting.

Cell Cycle-dependent Binding of Mad2 to Box1/2 of beta c-- Mad2 associates with various cell cycle-related proteins in a cell cycle phase-dependent manner (21, 22, 30, 35, 36). To determine whether the association between Mad2 and beta c is also affected during the cell cycle, we prepared HeLa cell lysates at various phases of the cell cycle. HeLa cells were arrested at G1 by a thymidine double block and released from arrest by removing thymidine. Cells were harvested at the time points indicated in Fig. 5A, and a portion was used to analyze the cell cycle. Cell lysates prepared from harvested cells were divided to two samples. With one being incubated with GST-box1/2 protein and precipitated with glutathione-Sepharose 4B beads. And the other immunoprecipitated with anti-p55 CDC (Cdc20) antibody. The co-precipitated Mad2 was then analyzed by Western blotting (Fig. 5A). As expected, association between Mad2 and p55CDC was not observed at the G1/S phase but became slightly visible 6 h after release from the thymidine block and was dramatically enhanced with a peak at 9 h, as reported (30). At that time, the total amount of Mad2 found in the total lysate (bottom panel) had increased between 6 and 9 h and then continued to increase gradually along with cell cycle progression. A low level of association between Mad2 and box1/2 was observed 9 h after the release from the thymidine block. In contrast to the finding that the association of p55CDC and Mad2 was transient, the extent of association between Mad2 and box1/2 increased for at least 15 h. These results suggest that p55CDC and box1/2 may associate with Mad2 through different mechanisms. In addition, when GST-box1/2-precipitated membrane was blotted with anti-p55CDC, no band was observed, which meant that a triple complex of Mad2, p55CDC, and beta c may not have formed. Using fractionated cell lysates, we next examined whether or not the changes in the binding pattern were caused by a change in the subcellular localization of Mad2. The assay of GST-box1/2 and Mad2 binding was done as described in Fig. 5A except that fractionated HeLa cell lysates were used. HeLa cell lysates were divided into 0.6% Nonidet P-40 soluble fraction (cytoplasmic portion) and high salt-extracted fraction (nuclear fraction), and the binding assay using recombinant purified GST-box1/2 was done. The total amount of Mad2 in the fractions was analyzed by Western blotting. As shown in Fig. 5B, binding of Mad2 with GST-box1/2 was seen only with the cytoplasmic fraction. The time course of binding was similar to that observed for the total cell extract. In contrast, no visible binding was observed with Mad2 from the nuclear fraction, although there was a greater amount of Mad2 in this fraction. These results indicate that the change in the binding property between box1/2 and Mad2 may be regulated by a change in affinity, not by a change in subcellular localization. Using Ba/F3 cells, we next examined the binding property of Mad2 in various phases of cell cycle progression. Ba/F3 cells were depleted of mIL-3 for 12 h and then re-stimulated with hGM-CSF. At selected time points, cell cycle progression was analyzed by using propidium iodide (Fig. 5C), and Mad2 binding affinity for beta c or p55CDC was examined as done when HeLa cells were used. Intensities of bands were calculated, and relative values are presented (Fig. 5D). Binding patterns between Mad2 and p55CDC or beta c obtained with Ba/F3 cells were similar to those observed with HeLa cells.


View larger version (16K):
[in this window]
[in a new window]
 
Fig. 5.   Cell cycle-dependent association of Mad2 with box1/box2 region. A, HeLa cells were G1-arrested by using thymidine and released from the block by removing the thymidine. The whole cell lysates obtained at the indicated time points were divided to two portions, and proteins of both samples were precipitated either with anti-p55CDC antibody (upper panel) or GST-box1/2 (middle panel), and the co-precipitated Mad2 was analyzed by Western blotting. The amount of Mad2 in the total cell lysate was analyzed by Western blotting using anti-Mad2 antibody (bottom panel). IP, immunoprecipitation. In B, essentially the same experiments as in A were done except that HeLa cell lysates were fractionated into cytoplasm and nuclear portions. Then, both fractions were precipitated with GST-box1/2, and a part of each was subjected to Western blotting using anti-Mad2 antibody to examine the total amount of Mad2. C and D, Ba/F3 cells were depleted of mIL-3 and then re-stimulated by hGM-CSF. Cells were collected at the indicated time points, and immunoprecipitation using anti-p55CDC (triangle ) or -beta c (open circle ) antibodies or cell cycle analysis (C) were done. The intensity of co-immunoprecipitated Mad2 bands is also presented (D).


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Here, we identified Mad2 as a molecule interacting with the box1/2 region of hGM-CSFR beta c. Interaction of Mad2 with membrane protein was reported previously for the insulin receptor, where the C-terminal 30 amino acids of the insulin receptor was required for this interaction (27), and this region contained a sequence similar to the common motif observed in the box1 region of cytokine receptors (12). Because peptide analysis showed the importance of the conserved amino acid motif of the beta c box1 region for Mad2 binding, a similar motif may also play a role in the binding between Mad2 and the insulin receptor. The insulin receptor activates Jak1 and Jak2 (37), but the region of this receptor responsible for binding to Jak proteins has not yet been revealed. Because Jak2 is assumed to interact with the box1/2 region of cytokine receptors, it thus can be speculated that Jak proteins bind to the insulin receptor through the same region as Mad2. Mad2 dissociates from insulin receptor by insulin stimulation (27). We examined the effects of hGM-CSF stimulation on Mad2 binding with beta c, but no clear change of Mad2 and beta c binding state up to 10 h after hGM-CSF stimulation was observed (data not shown). However, Mad2/beta c association was increased after 12 h of hGM-CSF stimulation with the cell cycle progression. The addition of insulin induces tyrosine phosphorylation of the insulin receptor, and a C-terminal phosphorylated tyrosine residue is assumed to decrease binding affinity for Mad2 (27). In the case of beta c, the absence of a tyrosine residue in the box1/2 region may be a possible reason for the lack of effect of hGM-CSF for Mad2 and beta c binding in the early phase after stimulation.

The C terminus of Mad2 appeared to be important for binding with beta c. Previous studies showed the importance of the Mad2 C terminus for binding with other Mad2 partners such as Cdc20 and Mad1 in mammalian and yeast systems (38, 39). The Mad2 contains the HORMA (for Hop1p, Rev7p, and Mad2) domain (40), which was found by comparative analysis of Mad2 and other proteins. We found that a part of the HORMA domain of Mad2 C terminus contained a motif of the TPR (tetratrico peptide repeat) domain (41), which is known to play an important role in protein-protein interaction. The TPR-like motif is found only within Mad2 among other HORMA domain proteins, thus indicating the possibility that the unique feature of Mad2 interaction with other proteins can be explained by the combinational effects of TPR and HORMA domains.

Mad2 is known to change its affinity toward interacting molecules during cell cycle progression (35). Interestingly, the affinity of Mad2 for the box1/2 region also changed during cell cycle progression in both Ba/F3 and HeLa cells. We found that the C terminus of Mad2 was important for binding with beta c. Because one of the Mad2 M phase binding partners, p55CDC (Cdc20), binds to the C terminus of Mad2 (39), beta c and p55CDC may use a similar mechanism to bind to Mad2. When we examined the time course of the Mad2/beta c association precisely, the binding became visible slightly later than that of Mad2/p55CDC protein in both HeLa and Ba/F3 cells, suggesting that additional mechanisms may differently regulate the affinity of beta c and p55CDC for Mad2. We found that Mad2 recovered in the 0.6% Nonidet P-40-soluble fraction bound to GST-box1/2 but that no binding occurred with the fraction extracted by the high salt condition, suggesting that the change in binding property is mainly caused by a change in affinity rather than one in subcellular localization. The trigger and mechanism of its changing of binding affinity of Mad2 to other partner proteins has not been clarified. We speculate that Mad2 may be modified in response to hGM-CSF stimulation, because GM-CSF activates cascades of kinases. Indeed, at the C terminus region of Mad2, there are several potential phosphorylation sites, but no report has appeared to suggest phosphorylation of the Mad2. To examine posttranslational modification of Mad2, we extensively examined mobility profile of Mad2 by two-dimensional gel electrophoresis, but Mad2 prepared from different phases of the cell cycle had the same mobility profile (data not shown). Further examination of tyrosine phosphorylation by Western blotting showed no detectable tyrosine phosphorylation. Taken together, our data indicate that some other mechanism(s) than phosphorylation is probable for the modification of Mad2.

Mad2 plays a major role in the nucleus as a member of the APC complex, and changing of the subcellular localization of Mad2 during cell cycle progression was reported. Mad2 appeared within the kinetochore in the G2/M phase but disappeared after cytokinesis (42). We also observed immunohistochemically a similar pattern of the subcellular localization of Mad2 overexpressed in Ba/F3 cells (data not shown). We hypothesize that the cytokine receptor anchors Mad2 in the cytoplasm until the appropriate time and that after its release, Mad2 is translocated to the nucleus where it functions as a member of the M phase checkpoint. Because the binding affinity between Mad2 and beta c gradually increased after M phase, it is feasible that the cytokine receptor captures Mad2 after completion of spindle formation and keeps it until the appropriate time. As cytokine receptors are known to be internalized after ligand binding, the possibility exists that internalized GM-CSFR meets Mad2 in the cytoplasm.

The primary role of the beta c-box1/2 is thought to be interaction with Jak2, and Jak2 is responsible for all of the examined activities of GM-CSF (7). We examined whether the bindings of Jak2 and Mad2 to beta c compete with each other or not, but obtained no clear biochemical result. We examined the effects of overexpressed Mad2 on GM-CSF-dependent cell proliferation, but neither augmentation nor suppression was observed (data not shown). Furthermore, overexpression of Mad2 had no effect on GM-CSF-induced c-fos- or E2F target site promoter activation. Because all of these activities require Jak2 activation (7), Mad2 may not interfere with the binding of Jak2 to beta c in vivo.

The point of the cell cycle regulated by growth factors is assumed to be mainly in the G1/S phase transition. For example, the Ba/F3 cell line, which was used in this present study, is mIL-3-dependent, and classical experiments using transient stimulation of Ba/F3 cells indicate that the presence of cytokine only at the G1/S phase can promote completion of the whole cell cycle (data not shown). Most assays are employed to analyze signals and functions of growth factors that are early events after growth factor stimulation. Thus, although the regulation of biochemical events in the G1/S transition have been extensively studied, the regulation of the G2/M phase by growth factors has received less attention. How does the cytokine receptor contribute to M phase progression? Our results suggest new mechanism of regulation of the cell cycle by cytokine in the M phase.

    ACKNOWLEDGEMENTS

We are grateful for Drs. T. Itoh, A. Muto, and Y. Sakurai for discussion and Y. Aoki and Y. Izawa for technical assistance.

    FOOTNOTES

* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

|| To whom correspondence should be addressed: Dept. of Molecular and Developmental Biology, Inst. of Medical Science, University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan. Tel.: 81-3-5449-5660; Fax: 81-3-5449-5424; E-mail: sumiko@ims.u-tokyo.ac.jp.

Published, JBC Papers in Press, September 10, 2001, DOI 10.1074/jbc.M101488200

    ABBREVIATIONS

The abbreviations used are: GM-CSF, granulocyte-macrophage colony-stimulating factor; hGM-CSF, human granulocyte-macrophage colony-stimulating factor; GM-CSFR, granulocyte-macrophage colony-stimulating factor receptor; IL, interleukin; APC, anaphase promoting complex; GST, glutathione S-transferase; PCR, polymerase chain reaction; PAGE, polyacrylamide gel electrophoresis; TPR, tetratrico peptide repeat; HORMA, Hop1p, Rev7p, and Mad2.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Arai, K., Lee, F., Miyajima, A., Miyatake, S., Arai, N., and Yokota, T. (1990) Annu. Rev. Biochem. 59, 783-836[CrossRef][Medline] [Order article via Infotrieve]
2. Miyajima, A., Mui, A. L.-F., Ogorochi, T., and Sakamaki, K. (1993) Blood 82, 1960-1974[Free Full Text]
3. Watanabe, S., Mui, A. L.-F., Muto, A., Chen, J. X., Hayashida, K., Miyajima, A., and Arai, K. (1993) Mol. Cell. Biol. 13, 1440-1448[Abstract/Free Full Text]
4. Hayashida, K., Kitamura, T., Gorman, D. M., Arai, K., Yokota, T., and Miyajima, A. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 9655-9659[Abstract/Free Full Text]
5. Murakami, M., Hibi, M., Nakagawa, N., Nakagawa, T., Yasukawa, K., Yamanishi, K., Taga, T., and Kishimoto, T. (1993) Science 260, 1808-1810[Abstract/Free Full Text]
6. Sakamaki, K., Miyajima, I., Kitamura, T., and Miyajima, A. (1992) EMBO J. 11, 3541-3550[Medline] [Order article via Infotrieve]
7. Watanabe, S., Itoh, T., and Arai, K. (1996) J. Biol. Chem. 271, 12681-12686[Abstract/Free Full Text]
8. Okuda, K., and Griffin, J. (1997) Blood 90, 4759-4760[Abstract/Free Full Text]
9. Itoh, T., Liu, R., Yokota, T., Arai, K., and Watanabe, S. (1998) Mol. Cell. Biol. 18, 742-752[Abstract/Free Full Text]
10. Neubauer, H., Cumano, A., Muller, M., Wu, H., Huffstadt, U., and Pfeffer, K. (1998) Cell 93, 397-409[CrossRef][Medline] [Order article via Infotrieve]
11. Parganas, E., Wang, D., Stravopodis, D., Topham, D. J., Marine, J.-C., Teglund, S., Vanin, E. F., Bodner, S., Colamonici, O. R., van Deursen, J. M., Grosveld, G., and Ihle, J. N. (1998) Cell 93, 385-395[CrossRef][Medline] [Order article via Infotrieve]
12. Murakami, M., Narazali, M., Hibi, M., Yawata, H., Yasukawa, K., Hamaguchi, M., Taga, T., and Kishimoto, T. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 11349-11353[Abstract/Free Full Text]
13. Avalos, B. R., Hunter, M. G., Parker, J. M., Ceselski, S. K., Druker, B. J., Corey, S. J., and Mehta, V. B. (1995) Blood 85, 3117-3126[Abstract/Free Full Text]
14. Dinerstein, H., Lago, F., Goujon, L., Ferrag, F., Esposito, N., Finidori, J., Kelly, P. A., and Postel-Vinay, M. C. (1995) Mol. Endocrinol. 9, 1701-1707[Abstract/Free Full Text]
15. Wang, Y. D., and Wood, W. I. (1995) Mol. Endocrinol. 9, 303-311[Abstract/Free Full Text]
16. O'Neal, K. D., and Shearer, W. T. (1995) Mol. Cell. Biol. 15, 4657-4658[Medline] [Order article via Infotrieve]
17. O'Neal, K. D., Yu-, Lee, L. Y., and Shearer, W. T. (1995) Ann. N. Y. Acad. Sci. 766, 282-284[Medline] [Order article via Infotrieve]
18. Li, R., and Murray, A. W. (1991) Cell 66, 519-531[CrossRef][Medline] [Order article via Infotrieve]
19. Dobles, M., Liberal, V., Scott, M. L., Benezra, R., and Sorger, P. K. (2000) Cell 101, 635-645[CrossRef][Medline] [Order article via Infotrieve]
20. Pennisi, E. (1998) Science 279, 477-478[Free Full Text]
21. Fang, G., Yu, H., and Kirschner, M. W. (1998) Genes Dev. 12, 1871-1883[Abstract/Free Full Text]
22. Hwang, L. H., Lau, L. F., Smith, D. L., Mistrot, C. A., Hardwick, K. G., Hwang, E. S., Amon, A., and Murray, A. W. (1998) Science 279, 1041-1044[Abstract/Free Full Text]
23. Elledge, S. J. (1998) Science 279, 999-1000[Free Full Text]
24. Liu, Y. C., Pan, J., Zhang, C., Fan, W., Collinge, M., Bender, J. R., and Weissman, S. M. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 4313-4318[Abstract/Free Full Text]
25. Poelzl, G., Kasai, Y., Mochizuki, N., Shaul, P. W., Brown, M., and Mendelsohn, M. E. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 2836-2839[Abstract/Free Full Text]
26. Nelson, K. K., Schlondorff, J., and Blobel, C. P. (1999) Biochem. J. 343, 673-680
27. O'Neill, T. J., Zhu, Y., and Gustafson, T. A. (1997) J. Biol. Chem. 272, 10035-10040[Abstract/Free Full Text]
28. Miyajima, A., Schreurs, J., Otsu, K., Kondo, A., Arai, K., and Maeda, S. (1987) Gene (Amst.) 58, 273-281[CrossRef][Medline] [Order article via Infotrieve]
29. Takebe, Y., Seiki, M., Fujisawa, J., Hoy, P., Yokota, K., Arai, K., Yoshida, M., and Arai, N. (1988) Mol. Cell. Biol. 8, 466-472[Abstract/Free Full Text]
30. Wassmann, K., and Benezra, R. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 11193-11198[Abstract/Free Full Text]
31. O'Farrell, P. H. (1975) J. Biol. Chem. 250, 4007-4021[Abstract/Free Full Text]
32. Masaki, T., Tanabe, M., Nakamura, K., and Soejima, M. (1981) Biochim. Biophys. Acta 660, 44-50[Medline] [Order article via Infotrieve]
33. Munro, S., and Pelham, H. R. B. (1986) Cell 46, 291-300[CrossRef][Medline] [Order article via Infotrieve]
34. Quelle, F. W., Sato, N., Witthuhn, B. A., Inhorn, R. C., Eder, M., Miyajima, A., Griffin, J., and Ihle, J. N. (1994) Mol. Cell. Biol. 14, 4335-4341[Abstract/Free Full Text]
35. Li, Y., Gorbea, C., Mahaffey, D., Rechsteiner, M., and Benezra, R. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 12431-12436[Abstract/Free Full Text]
36. Kallio, M., Weinstein, J., Daum, J. R., Burke, D. J., and Gorbsky, G. J. (1998) J. Cell Biol. 141, 1393-1406[Abstract/Free Full Text]
37. Gual, P., Baron, V., Lequoy, V., and Van Obberghen, E. (1998) Endocrinology 139, 884-893[Abstract/Free Full Text]
38. Chen, R. H., Brady, D. M., Smith, D., Murray, A. W., and Hardwick, K. G. (1999) Mol. Biol. Cell 10, 2607-2618[Abstract/Free Full Text]
39. Luo, X., Fang, G., Coldiron, M., Lin, Y., Yu, H., Kirschner, M. W., and Wagner, G. (2000) Nat. Struct. Biol. 7, 224-229[CrossRef][Medline] [Order article via Infotrieve]
40. Aravind, L., and Koonin, E. V. (1998) Trends Biochem. Sci. 23, 284-286[Medline] [Order article via Infotrieve]
41. Lamb, J. R., Tugendreich, S., and Hieter, P. (1995) Trends Biochem. Sci. 20, 257-259[CrossRef][Medline] [Order article via Infotrieve]
42. Li, Y., and Benezra, R. (1996) Science 274, 246-248[Abstract/Free Full Text]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
BloodHome page
S. Ito, C. R. Mantel, M.-K. Han, S. Basu, S. Fukuda, S. Cooper, and H. E. Broxmeyer
Mad2 is required for optimal hematopoiesis: Mad2 associates with c-Kit in MO7e cells
Blood, March 1, 2007; 109(5): 1923 - 1930.
[Abstract] [Full Text] [PDF]


Home page
Plant CellHome page
K. Aoki, N. Suzui, S. Fujimaki, N. Dohmae, K. Yonekura-Sakakibara, T. Fujiwara, H. Hayashi, T. Yamaya, and H. Sakakibara
Destination-Selective Long-Distance Movement of Phloem Proteins
PLANT CELL, June 1, 2005; 17(6): 1801 - 1814.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
D. Pati, B. R. Haddad, A. Haegele, H. Thompson, F. S. Kittrell, A. Shepard, C. Montagna, N. Zhang, G. Ge, S. K. Otta, et al.
Hormone-Induced Chromosomal Instability in p53-Null Mammary Epithelium
Cancer Res., August 15, 2004; 64(16): 5608 - 5616.
[Abstract] [Full Text] [PDF]


Home page
JCBHome page
M. Umezu-Goto, Y. Kishi, A. Taira, K. Hama, N. Dohmae, K. Takio, T. Yamori, G. B. Mills, K. Inoue, J. Aoki, et al.
Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production
J. Cell Biol., July 22, 2002; 158(2): 227 - 233.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
276/45/41803    most recent
M101488200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Takeda, M.
Right arrow Articles by Watanabe, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Takeda, M.
Right arrow Articles by Watanabe, S.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2001 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement